v3.26.1
Segment Information - Schedule of Sales and Earnings (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Net Sales to External Customers $ 12,593   $ 11,142   $ 23,757 $ 21,500
Cost of Products Sold (5,325)   (4,854)   (10,215) (9,322)
Research and Development (892)   (725)   (1,659) (1,441)
Selling, General, and Administrative (4,025)   (3,091)   (7,765) (6,152)
Operating Earnings 1,693   2,052   3,038 3,745
Amortization of intangible assets $ (658)   $ (420)   $ (1,080) $ (840)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Other, net (b)   Other, net (b)   Other, net (b) Other, net (b)
Earnings before taxes $ 1,524   $ 2,150   $ 2,973 $ 3,928
Annual share-based awards recognized in first quarter (as a percent)   45.00%   45.00%    
Share-based compensation expense         321  
Operating Segments            
Segment Reporting [Line Items]            
Net Sales to External Customers 12,588   11,137   23,750 21,492
Cost of Products Sold (5,255)   (4,768)   (10,044) (9,211)
Research and Development (840)   (681)   (1,534) (1,327)
Selling, General, and Administrative (3,275)   (2,756)   (6,050) (5,362)
Operating Earnings 3,218   2,932   6,122 5,592
Operating Segments | Established Pharmaceuticals            
Segment Reporting [Line Items]            
Net Sales to External Customers 1,499   1,383   2,925 2,643
Cost of Products Sold (650)   (631)   (1,294) (1,200)
Research and Development (48)   (43)   (89) (85)
Selling, General, and Administrative (419)   (363)   (795) (714)
Operating Earnings 382   346   747 644
Operating Segments | Nutritional Products            
Segment Reporting [Line Items]            
Net Sales to External Customers 2,144   2,212   4,161 4,358
Cost of Products Sold (1,148)   (1,155)   (2,237) (2,279)
Research and Development (54)   (54)   (108) (106)
Selling, General, and Administrative (574)   (585)   (1,137) (1,161)
Operating Earnings 368   418   679 812
Operating Segments | Diagnostic Products            
Segment Reporting [Line Items]            
Net Sales to External Customers 3,092   2,173   5,272 4,227
Cost of Products Sold (1,532)   (1,224)   (2,774) (2,376)
Research and Development (268)   (154)   (423) (305)
Selling, General, and Administrative (793)   (423)   (1,241) (815)
Operating Earnings 499   372   834 731
Operating Segments | Medical Devices            
Segment Reporting [Line Items]            
Net Sales to External Customers 5,853   5,369   11,392 10,264
Cost of Products Sold (1,925)   (1,758)   (3,739) (3,356)
Research and Development (470)   (430)   (914) (831)
Selling, General, and Administrative (1,489)   (1,385)   (2,877) (2,672)
Operating Earnings 1,969   1,796   3,862 3,405
Other            
Segment Reporting [Line Items]            
Net Sales to External Customers 5   5   7 8
Reconciling Items            
Segment Reporting [Line Items]            
Corporate functions and plan benefit costs (45)   (65)   (110) (93)
Net interest expense (299)   (50)   (367) (99)
Share-based compensation (168)   (142)   (806) (431)
Amortization of intangible assets (658)   (420)   (1,080) (840)
Other, net $ (524)   $ (105)   $ (786) $ (201)